NCT06029010View on ClinicalTrials.gov

An Observational Study to Learn More About the Long-Term Responses to Treatment With Regorafenib in Patients With Metastatic Colorectal Cancer in the United States

CompletedOBSERVATIONAL
Enrollment

2,326

Participants

Timeline

Start Date

August 31, 2023

Primary Completion Date

January 27, 2025

Study Completion Date

January 27, 2025

Conditions
Metastatic Colorectal Cancer
Interventions
DRUG

Regorafenib (Stivarga, BAY73-4506)

Follow clinical administration.

Trial Locations (1)

07981

Many Locations, Multiple Locations

Sponsors

Lead Sponsor

Bayer
All Listed Sponsors
lead

Bayer

INDUSTRY

NCT06029010 - An Observational Study to Learn More About the Long-Term Responses to Treatment With Regorafenib in Patients With Metastatic Colorectal Cancer in the United States | Biotech Hunter | Biotech Hunter